Patents by Inventor Marcella A. Gilmore

Marcella A. Gilmore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080161226
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Application
    Filed: August 27, 2007
    Publication date: July 3, 2008
    Applicant: Allergan, Inc.
    Inventors: Lance E. Steward, Joseph Francis, Ester Fernandez-Salas, Marcella A. Gilmore, Shengwen Li, J. Oliver Dolly, Kei Roger Aoki
  • Publication number: 20080138893
    Abstract: Nucleic acid molecules that comprise modified open reading frames providing increased expression of the encoded active BoNT/E in a heterologous cell, expression constructs and cells comprising such nucleic acid molecules and methods useful for expressing the encoding active BoNT/E from such nucleic acid molecules, expression constructs and cells.
    Type: Application
    Filed: June 9, 2005
    Publication date: June 12, 2008
    Inventors: Lance E. Steward, Marcella A. Gilmore, Ester G. Fernandez-Salas, Shengwen Li, Ronald G. Miller, Kei Roger Aoki
  • Patent number: 7374896
    Abstract: The present invention provides a nucleic acid molecule which contains a nucleotide sequence encoding a SNAP-25 substrate which includes (i) a green fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a portion of SNAP-25 that includes a BoNT/A, BoNT/C1 or BoNT/E recognition sequence containing a cleavage site, where the cleavage site intervenes between the green fluorescent protein and the first partner of the affinity couple. Further provided herein is a nucleic acid molecule which contains a nucleotide sequence encoding a tagged toxin substrate which includes (i) a fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a clostridial toxin recognition sequence containing a cleavage site, where the cleavage site intervenes between the fluorescent protein and the first partner of the affinity couple.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: May 20, 2008
    Assignee: Allergan, Inc.
    Inventors: Lance E. Steward, Marcella A. Gilmore, Kei R. Aoki
  • Publication number: 20080096248
    Abstract: The specification discloses modified Clostridial toxins comprising a Clostridial toxin enzymatic domain, a Clostridial toxin translocation domain and an enhanced Clostridial toxin binding domain; polynucleotide molecules encoding such modified Clostridial toxins; and method of producing such modified Clostridial toxins.
    Type: Application
    Filed: March 14, 2006
    Publication date: April 24, 2008
    Applicant: Allergan, Inc.
    Inventors: Lance Steward, Ester Fernandez-Salas, Joseph Francis, Shengwen Li, Marcella Gilmore, Kei Roger Aoki
  • Publication number: 20080057575
    Abstract: Nucleic acid molecules that comprise modified open reading frames providing increased expression of the encoded active BoNT/A in a heterologous cell, expression constructs and cells comprising such nucleic acid molecules and methods useful for expressing the encoding active BoNT/A from such nucleic acid molecules, expression constructs and cells.
    Type: Application
    Filed: August 3, 2005
    Publication date: March 6, 2008
    Applicant: ALLERGAN, INC.
    Inventors: Ester Fernandez-Salas, Lance Steward, Ronald Miller, Kei Aoki, Marcella Gilmore, Shengwen Li
  • Publication number: 20080032930
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Application
    Filed: August 1, 2007
    Publication date: February 7, 2008
    Applicant: Allergan, Inc.
    Inventors: Lance Steward, Joseph Francis, Ester Fernandez-Salas, Marcella Gilmore, Shengwen Li, J. Dolly, Kei Aoki
  • Publication number: 20080032931
    Abstract: Compositions comprising activatable recombinant neurotoxins and polypeptides derived therefrom. The invention also comprises nucleic acids encoding such polypeptides, and methods of making such polypeptides and nucleic acids.
    Type: Application
    Filed: August 6, 2007
    Publication date: February 7, 2008
    Inventors: Lance Steward, Joseph Francis, Ester Fernandez-Salas, Marcella Gilmore, Shengwen Li, J. Dolly, Kei Aoki
  • Publication number: 20070275477
    Abstract: The present invention provides a method of determining the proximity, or changes in the proximity of two or more molecular features labeled with fluorophores able to undergo DARET. In preferred embodiments the change in proximity of molecular features in a sample is correlated with changes in the fluorescence polarization of the sample, and may be monitored in real time.
    Type: Application
    Filed: October 11, 2006
    Publication date: November 29, 2007
    Inventors: Marcella Gilmore, Dudley Williams, Lance Steward, Kei Aoki
  • Publication number: 20070243565
    Abstract: Clostridial toxin substrates comprising a lanthanide donor complex, an acceptor, and a Clostridial toxin recognition sequence including a cleavage site; methods for determining the activity of a Clostridial toxin from a test sample using such Clostridial toxin substrates; cell compositions comprising such Clostridial toxin substrates and a Clostridial toxin receptor; and methods for determining the activity of a Clostridial toxin from a test sample using such cell compositions.
    Type: Application
    Filed: May 23, 2007
    Publication date: October 18, 2007
    Inventors: Dudley Williams, Marcella Gilmore, Lance Steward, Marc Verhagen, Kei Aoki, Ester Fernandez-Salas
  • Publication number: 20060211619
    Abstract: The present invention is directed to multivalent Clostridial neurotoxin derivatives having more than one binding domain directed to a cell surface feature of a target cell. Such modified neurotoxins are useful as therapeutic compositions to prevent exocytosis and secretion by the target cell. Conditions in which such compositions man be useful include, without limitation, disorders of the sensory or motor nervous system, acute or chronic pain, cancer, pancreatitis, hyperhydrosis, glandular disorders, viral infections, cystic fibrosis and the like. The invention is also directed to methods of using and administering such a composition, and methods of treating a given condition using such a composition.
    Type: Application
    Filed: March 15, 2006
    Publication date: September 21, 2006
    Inventors: Lance Steward, Fernandez-Salas Ester, Joseph Francis, Shengwin Li, Marcella Gilmore, Kei Aoki
  • Publication number: 20060154314
    Abstract: The present invention provides a nucleic acid molecule which contains a nucleotide sequence encoding a SNAP-25 substrate which includes (i) a green fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a portion of SNAP-25 that includes a BoNT/A, BoNT/C1 or BoNT/E recognition sequence containing a cleavage site, where the cleavage site intervenes between the green fluorescent protein and the first partner of the affinity couple. Further provided herein is a nucleic acid molecule which contains a nucleotide sequence encoding a tagged toxin substrate which includes (i) a fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a clostridial toxin recognition sequence containing a cleavage site, where the cleavage site intervenes between the fluorescent protein and the first partner of the affinity couple.
    Type: Application
    Filed: August 13, 2004
    Publication date: July 13, 2006
    Applicant: Allergan Sales, Inc.
    Inventors: Lance Steward, Marcella Gilmore, Kei Aoki
  • Publication number: 20060063222
    Abstract: The present invention provides a method of determining the presence or activity of a clostridial toxin by (a) treating with a sample, under conditions suitable for clostridial toxin protease activity, a clostridial toxin substrate which includes a fluorophore; a bulking group; and a clostridial toxin recognition sequence containing a cleavage site that intervenes between the fluorophore and the bulking group; (b) exciting the fluorophore with plane polarized light; and (c) determining fluorescence polarization of the treated substrate relative to a control substrate, where a change in fluorescence polarization of the treated substrate as compared to fluorescence polarization of the control substrate is indicative of the presence or activity of the clostridial toxin.
    Type: Application
    Filed: September 22, 2004
    Publication date: March 23, 2006
    Applicant: ALLERGAN, INC., a corporation
    Inventors: Dudley Williams, Marcella Gilmore, Lance Steward, Marc Verhagen, Kei Aoki
  • Publication number: 20060063221
    Abstract: The present invention provides a clostridial toxin substrate that contains (a) a lanthanide donor complex; (b) an acceptor having an absorbance spectrum overlapping the emission spectrum of the lanthanide donor complex; and (c) a clostridial toxin recognition sequence containing a cleavage site that intervenes between the lanthanide donor complex and the acceptor, where, under the appropriate conditions, resonance energy transfer is exhibited between the lanthanide donor complex and the acceptor.
    Type: Application
    Filed: September 21, 2004
    Publication date: March 23, 2006
    Inventors: Dudley Williams, Marcella Gilmore, Lance Steward, Marc Verhagen, Kei Aoki
  • Publication number: 20050100973
    Abstract: The present invention provides a nucleic acid molecule which contains a nucleotide sequence encoding a SNAP-25 substrate which includes (i) a green fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a portion of SNAP-25 that includes a BoNT/A, BoNT/C1 or BoNT/E recognition sequence containing a cleavage site, where the cleavage site intervenes between the green fluorescent protein and the first partner of the affinity couple. Further provided herein is a nucleic acid molecule which contains a nucleotide sequence encoding a tagged toxin substrate which includes (i) a fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a clostridial toxin recognition sequence containing a cleavage site, where the cleavage site intervenes between the fluorescent protein and the first partner of the affinity couple.
    Type: Application
    Filed: August 13, 2004
    Publication date: May 12, 2005
    Applicant: Allergan Sales, Inc.
    Inventors: Lance Steward, Marcella Gilmore, Kei Aoki